Research programme: neurological disorder therapeutics - Biscayne Pharmaceuticals

Drug Profile

Research programme: neurological disorder therapeutics - Biscayne Pharmaceuticals

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Insero Health
  • Developer Biscayne Pharmaceuticals
  • Class Alkaloids; Sesquiterpenes
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Epilepsy; Neurological disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Epilepsy in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
  • 05 Oct 2015 Insero Health has been acquired by Biscayne Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top